Aprocitentan

Aprocitentan (brand name Tryvio) is an FDA-approved, once-daily oral dual endothelin receptor antagonist (ETA and ETB) approved in March 2024 for treating resistant hypertension in adults. It acts by inhibiting the vasoconstrictive effects of endothelin-1, reducing blood pressure in patients already taking at least three other antihypertensive classes. Due to risks of embryo-fetal toxicity, it requires a restricted REMS program.